|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Departments of Leukemia, Laboratory Medicine,
and Bioimmunotherapy, The University of Texas M. D. Anderson
Cancer Center, Houston, Texas.
The objective of this study was to examine the correlation between
serum interleukin-6 (IL-6) and IL-10 levels and outcome in chronic
lymphocytic leukemia (CLL). Serum IL-6 and IL-10 levels were measured
by enzyme-linked immunoabsorbent assays from 159 and 151 CLL patients,
respectively, and from healthy control subjects (n = 55 [IL-6];
n = 37 [IL-10]). Cytokine levels were correlated with clinical
features and survival. Serum IL-6 levels were higher in CLL patients
(median, 1.45 pg/mL; range, undetectable to 110 pg/mL) than in control
subjects (median, undetectable; range, undetectable to 4.30 pg/mL)
(P < .0001). Serum IL-10 levels were higher in CLL
patients (median, 5.04 pg/mL; range, undetectable to 74 pg/mL) than in
normal volunteers (median, undetectable; range, undetectable to 13.68 pg/mL) (P < .00001). Assays measuring both Epstein-Barr
virus-derived and human IL-10 yielded higher values than assays
measuring primarily human IL-10 (P < .05). Patients with
elevation of serum IL-6 or IL-10 levels, or both, had worse median and
3-year survival (log rank P < .001) and unfavorable characteristics (prior treatment, elevated
Interleukin-6 (IL-6) is a pleiotropic cytokine
produced by a variety of cell types, including fibroblasts, endothelial
cells, monocytes, normal hematopoietic cells, and
lymphocytes.1-3 Several earlier studies suggested a
possible role for dysregulated production of IL-6 in malignant
lymphomas. For instance, IL-6 messenger RNA and protein expression has
been found in lymphoma cells using immunohistochemical
stains,4-9 and the degree of positivity correlates with
the proliferative rate of the malignant cells.9
Furthermore, acquired immunodeficiency syndrome (AIDS)-related B-cell
lymphoma cell lines produce large amounts of IL-6.10
Expression of an exogenous IL-6 gene in human Epstein-Barr virus
(EBV)-infected cells confers growth advantage and
tumorigenicity,11 and, in transgenic mice, IL-6 expression
has been associated with the development of
lymphomas.12
Serum IL-6 levels have been correlated with an increased risk for
development of lymphoma in patients with AIDS10 and in renal transplant recipients.13 Serum IL-6 levels are
increased in diffuse large cell lymphomas, associated with adverse
prognostic features, and predictive of a poor failure-free and overall
survival in multivariate analysis.14,15 Interestingly,
serum IL-6 levels may also be elevated16,17 and correlate
with poor prognostic features and an inferior outcome in Hodgkin
disease,17,18 indolent non-Hodgkin lymphomas
(NHLs),19 renal cell carcinoma,20 prostatic cancer,21 ovarian cancer,22 and multiple
myeloma.23,24
Interleukin-10 (IL-10) is a pleiotropic cytokine produced by type 2 helper cells (Th2),25 as well as monocytes and
macrophages, and normal and neoplastic B lymphocytes.26-28
It is highly homologous to an open reading frame of EBV called BCRF1,
and EBV infection of B cells up-regulates IL-10 production. IL-10
production has strong immunosuppressive effects via inhibition of Th1
type cytokines, including interferon-gamma and
interleukin-2.25 IL-10 has a potent stimulating effect on
B cells, inducing proliferation and differentiation. Interestingly, in
cell lines derived from B-cell lymphomas, IL-10 has been found to serve
as an autocrine growth factor.29-31 Serum IL-10 levels
have been found to be important prognostic factors for Hodgkin lymphoma
and, when assays that detect both human and viral IL-10 are employed,
for NHLs.32-36
In this study, we measured the pretreatment serum IL-6 and IL-10 levels
in a large cohort of patients with chronic lymphocytic leukemia (CLL)
to determine if high IL-6 and/or IL-10 levels correlate with disease
features and outcome.
Patients
Control subjects
IL-6 assays IL-6 levels were assayed in duplicate with all values expressed as a mean of the 2 determinations. A standard curve was generated, using known concentrations of recombinant human IL-6. The concentration of IL-6 in the patient and control serum samples was then determined from the standard curve. IL-6 was measured, using a validated commercial enzyme-linked immunosorbent assay (ELISA) (Quantikine, R&D Systems, Minneapolis, MN). This assay uses a solid-phase murine monoclonal anti-IL-6 antibody, bound to microtiters plates, that captures IL-6 in the sample assayed. Unbound protein is removed by washing, and a polyclonal anti-IL-6 antibody conjugated to horseradish peroxidase is added, with any excess conjugated antibody removed by further washing. The IL-6 bound is quantified by the addition of substrate solution (containing stabilized hydrogen peroxide and stabilized chromogen [tetramethylbenzidine]). If antibody-peroxidase conjugate is present, the substrate is oxidized, and the intensity of the color that develops is proportional to the amount of bound IL-6. The reaction is stopped after 20 minutes of incubation at room temperature, and the color intensity is quantified by using a microtiter plate reader at a wavelength of 450 nm. The manufacturer reports an intra-assay coefficient of variation of 2.7% to 4.2% at 5.2 to 107 ng/mL, and an inter-assay coefficient of variation 2.4% to 7% at 4.7 to 107 pg/mL. No cross-reactivity has been detected with any human cytokines detected to date. All values for IL-6 were converted to the NIBSC/WHO standard assay, using a correction factor according to the manufacturer's instructions. The assay has a lower sensitivity level of 0.9 pg/mL (corrected to WHO standard).38IL-10 assays Two IL-10 ELISAs were run. The reason for running 2 assays was based on previous studies which demonstrated that, in NHL, IL-10 levels are higher if measured by an ELISA that detects both viral and human IL-10 than if measured by an ELISA that discerns only human IL-10.35 Furthermore, correlation with prognosis is seen, using the former, but not the latter, assay.32-35The ENDOGEN Inc (Cambridge, MA) assay detects both viral and human IL-10 (as per manufacturer) and was used to test 159 CLL serum samples and all the normal control samples. For comparison purposes, the second IL-10 assay (detecting predominantly human IL-10 [as per manufacturer]) was used in a smaller subgroup (Cytoscreen, Biosource International, Camarillo, CA). IL-10 levels were assayed in duplicate with all values expressed as a mean of the 2 determinations. A standard curve was generated, using known concentrations of recombinant human IL-10. The concentration of IL-10 in the patient and control serum samples was then determined from the standard curve. As mentioned above, for most patients, IL-10 was measured, using a validated commercial ELISA test (Endogen). This assay uses an antihuman IL-10 biotinylated-antibody reagent and antihuman IL-10 antibody, bound to microtiters plates, that captures IL-10 in the sample assayed. Unbound protein is removed by washing, and a dilute streptavidin conjugated to horseradish peroxidase is added, with any excess conjugated antibody removed by further washing. The IL-10 bound is quantified by the addition of substrate solution. If antibody-peroxidase conjugate is present, the substrate is oxidized, and the intensity of the color that develops is proportional to the amount of bound IL-10. The reaction is stopped after 30 minutes of incubation at room temperature, and the color intensity is quantified by using a microtiter plate reader set at a wavelength of 450 nm. The manufacturer reports an intra-assay coefficient of variation of less than 10%, and a interassay coefficient of variation of less than 10%. No cross-reactivity has been detected with any human cytokines detected to date. The assay has a lower sensitivity level of 3 pg/mL. As discussed above, serum from a small group of patients was assessed,
using an IL-10 assay from Biosource International. In brief, the assay
uses a mouse monoclonal antibody (MoAb) specific for human IL-10 coated
onto microtiter wells into which samples were pipetted followed by the
addition of a second mouse anti-IL-10 MoAb (which is biotinylated).
Free antibody is removed by further washing, and
streptavidin-peroxidase is added. A final wash removes unbound enzyme,
and, subsequently, a substrate solution (tetramethyl benzidine) is
added that acted upon by any bound enzyme to produce color. After 30 minutes, the reaction is stopped, and the absorbance is read on a
microtiter plate reader at 450 nm. The intensity of the color is
directly proportional to the IL-10 present in the assayed sample. The
lower sensitivity of the assay is 5 pg/mL as per the manufacturer.
There is no cross-reactivity of this assay with viral IL-10, or human
IL-1a, IL-1b, IL-2, IL-6, or tumor necrosis factor Determination of intracytoplasmic cytokine synthesis by B-CLL cells Preparation for the detection of cytokines in the cellular cytoplasms was done as previously described.39 Blood samples from B-CLL patients with a white blood cell (WBC) count more than 15 × 109/L were diluted to 15 × 109/L to bring the WBC to within normal range. Blood (500 µL) was incubated at 37°C with 10 µg of brefeldin-A (a nontoxic but potent inhibitor of intracellular transport; Sigma Chemical, St Louis, MO) for 4 hours. To determine surface immunophenotype of the B cells, the cells were washed and stained with anti-CD19-peridinin chlorophyll protein (PerCP) and anti-CD5-fluorescein isothiocyanate (FITC) for 15 minutes in the dark at ambient temperature. Next, the cells were treated with a permeabilization solution (Becton Dickinson, Mountain View, CA) for 1 hour at 37°C to allow entry of the anti-cytokine monoclonal antibody. Finally, the cells were stained with a cytokine-specific MoAb conjugated with phycoerythrin to detect IL-6 or IL-10. All cell preparations were fixed in a solution of 1% paraformaldehyde and stored at 4°C until analysis by the FACSCalibur flow cytometer. (Antibodies for these experiments were obtained from Becton Dickinson, Franklin Lakes, NJ.)The analysis was conducted by gating on CD19-PerCP and side scatter to
identify CD19+ B cells among the 8000 total events
acquired. List-mode multiparameter data files (each file with forward
scatter, side scatter, and 3 fluorescence parameters) were analyzed,
using the CellQuest software program (Becton Dickinson). Isotype
controls were used to verify the staining specificity of experimental
conditions and as a guide for setting markers to delineate positive and
negative populations. Cytokine synthesis by CD19+ B cells
was determined in cells reactive to versus those nonreactive to
anti-CD5-FITC. This analytical approach permitted the determination of
IL-6 and IL-10 syntheses in CD19+ CD5+ (B-CLL)
and CD19+ CD5 Statistical analysis The statistical estimation of distribution of survival times was performed, using the Kaplan-Meier method.40 For survival analysis, all patients still alive were censored at the date of last follow-up. The starting time for all survival analyses was the date of sample collection. Comparisons between survivals were made, using the log-rank method.Categoric data were compared, using the chi-square test or Fisher exact test as indicated,41 and continuous data were compared, using the Mann-Whitney test or Kruskal-Wallis test as appropriate.42 Paired sample data (for intracytoplasmic detection of cytokines in cell subsets) were compared, using the Wilcoxon signed rank test. Comparison of IL-6 and IL-10 levels between CLL patients and control subjects was done as continuous data. For statistical purposes, all IL-6 levels below the detection limit of the assay were regarded as equivalent to 0.9 pg/mL, and all IL-10 levels (Endogen) below the limit of detection were regarded as equivalent to 3pg/mL. All P values given are 2 sided.
Control subjects Thirty-nine (71%) of 55 normal volunteers had a serum IL-6 level below the limit of detection of the assay (< 0.9 pg/mL). The serum IL-6 levels in the entire group ranged from < 0.9 pg/mL to 4.30 pg/mL (median, < 0.9 pg/mL). We, therefore, defined any serum level of 4.30 pg/mL as elevated. (The same cutoff was used for
intermediate-grade lymphomas in our previous
publication.15)
Thirty-seven normal volunteers were tested for serum IL-10 levels (Endogen), with 36 (97%) of 37 having nondetectable values (range, < 3-13.68 pg/mL). A cut-point value greater than 10 pg/mL was defined as an elevated value. Patients with CLL One-hundred seventy-seven patients with CLL were studied for serum IL-6 (n = 151), serum IL-10 (n = 159), or both cytokines (n = 133). Their clinical features are listed in Table 1. The serum IL-6 levels were undetectable in 62 (41%) of 151 patients compared with 71% of control subjects (P < .0001), and 36 (24%) CLL patients had values above the upper limit of the normal range (4.3 pg/mL) (P < 0.0001) (Figure 1).
The serum IL-10 levels (Endogen; detects both viral and human
IL-10) were undetectable in 60 (38%) of the 159 patients compared to
97% of normal volunteers (P < .0001) and elevated to
greater than 10 pg/mL in 34% of patients compared to 3% of normal
volunteers (P < .0001) (Figure
2). The median value of serum IL-10 in
the patients was 5.04 pg/mL (range, < 3-74 pg/mL).
In a small subset of patients (n = 20), a second IL-10 assay was used (Biosource). This assay detects human IL-10 only. Despite a level of sensitivity that was similar to that of the Endogen assay, the serum IL-10 level was detectable in only one patient using the Biosource assay. In contrast, the median serum IL-10 values for these 20 CLL patients was 8.1 pg/mL (range, undetectable to 44.3 pg/mL) by using the assay that detects both viral and human IL-10 (Endogen) (P < .01). These data suggest that in CLL, as in NHL,35 results may differ, depending on the assay method used, and that IL-10 levels are higher when assays capable of measuring both viral and human IL-10 are employed. Correlation of serum IL-6 and serum IL-10 levels with disease characteristics/transformation Higher serum IL-6 levels correlated with Rai stage III and IV (P = .0001), previous treatment (P = .0004), elevated 2-microglobulin level (2 mg/L)
(P < .001), elevated serum lactate dehydrogenase (LDH)
levels (P = .02), and age of greater than or equal to 60 years old (P = .003, Mann-Whitney test) (Table
2).
Higher serum IL-10 levels were associated with elevated LDH
(P = .000002), previous treatment (P = .005),
elevated
Richter transformation (n = 10) and progression to prolymphocytic leukemia (n = 5) occurred in a total of 15 patients (after sample collection). Transformation/progression was more common in patients with at least one cytokine elevation (13 of 74), compared to those patients without elevation (2 of 103) (P = .0005). Finally, samples from 15 patients (with initially elevated IL-6 and IL-10 levels), who achieved complete remission and were at least 3 months after their last therapy, were available. Both IL-6 and IL-10 levels were within normal range in these patients at this time point. Correlation of serum IL-6 and IL-10 levels and other prognostic features with survival With a median follow-up of 30 months, 135 patients are still alive. Patients with elevated serum IL-6 levels (>4.30 pg/mL) had decreased 2- and 3-year survival (61% and 51%, respectively) compared with patients with low levels (median survival not reached, 2-year survival 90%, 3-year survival 81%, log rank P = .00043) (Table 4 and Figure 3). Elevated serum IL-10 level (>10 pg/mL) was also associated with worse survival (median survival 32 months, 2-year and 3-year survival 62% and 45%, respectively) than patients with lower levels (median survival not reached, 2-year and 3-year survival of 92% and 85%, respectively; P < .000001) (Table 4 and Figure 4). When both cytokines were used to predict survival, 3 groups were formed according to the number of cytokines increased: zero, one, or both elevated, with median survival not reached, 36 months, and 19 months (P < .00001) (Figure 5). Elevated Rai stage, elevated2-microglobulin, and previous treatment correlated with
shorter survival (Table 4).
When Cox regression multivariate analysis was performed (with IL-6,
IL-10, and
Determination of intracytoplasmic cytokine synthesis by B-CLL cells In both previously treated and untreated CLL patients, the percentage of IL-10-positive B cells was significantly higher among the B cells that were not derived from the leukemic clone (CD19+, CD5 ) compared to those derived from
the leukemic clone (CD19+, CD5+) (mean ± SEM = 14.6% ± 8.7 versus 2.0% ± 1.9% [P = .03,
Wilcoxon signed rank test] [untreated patients, n = 7] and
mean ± SEM = 58.8% ± 18.6% versus 6.0% ± 2.2%
[P = .02] [previously treated patients, n = 7]). In
regard to IL-6, the source of IL-6 did not appear to be either the
malignant or the normal B cells (mean ± SEM = 1.96% ± 1.0
[CD19+, CD5 cells] versus 0% ± 0%
[CD19+, CD5+ cells] [P = not
significant] [untreated patients, n = 9] and mean ± SEM = 0% ± 0% [CD19+, CD5 cells]
versus 0% ± 0% [CD19+, CD5+ cells]
[P = not significant] [previously treated
patients, n = 7]).
IL-6 in lymphoproliferative disorders Several reports have demonstrated that serum IL-6 levels are elevated in patients with aggressive NHL14-17,24,43-46 and correlate with shorter failure-free survival.14,15,17 In our current study, we analyzed the serum levels of IL-6 in 151 CLL patients and demonstrated that a serum level of IL-6 above the range in our normal control subjects (4.30 pg/mL) is found in 24% of those individuals. A previous study reported that only 15% of patients with low-grade lymphoma have elevated serum IL-6 levels, but the cut point used in that study was higher (5 pg/mL)25 than the one in our study (4.30 pg/mL). In contrast, 35% to 78% of the patients with aggressive lymphomas have elevated serum IL-6 levels.14,15,17,23,43-47We found that, in CLL, high serum IL-6 levels correlated with
unfavorable phenotypic features of the disease such as advanced Rai
stage, older age, previous treatment, and elevated
Serum IL-6 levels show significant correlation with the overall survival. The 3-year survival for the group of patients with an elevated serum IL-6 was 51% (95% confidence interval [CI], 33%-69%), whereas the 3-year survival was 81% (95% CI, 72%-91%) in patients with normal serum IL-6 levels (P = .0004) (Figure 3). Similar correlation with survival has been seen in diffuse large cell lymphomas.14,15 However, in the latter disorder, serum IL-6 levels tend to be elevated in a much larger proportion of patients and also correlated with complete remission rate and with failure-free survival.15 It therefore appears that IL-6 levels are more often elevated in the more aggressive lymphomas, and it is conceivable that measurement of serum IL-6 levels may help to identify a subgroup of patients whose disease is beginning to evolve to a more aggressive form even though morphologic evidence of transformation is not yet evident. In keeping with this notion, Richter transformation and/or evolution to prolymphocytic leukemia was significantly more common in our CLL patients who had elevation of at least one cytokine (IL-6 and/or IL-10) compared to those without cytokine elevation. The source and role of IL-6 in patients with NHL and CLL is currently being investigated. Evidence from the literature suggests that both the lymphoma cells themselves and benign reactive lymphocytes in lymphomatous nodes can produce IL-6.4-9,44,47,52 In CLL, however, leukemic cells do not appear to be the source of IL-6.53 As to the role of IL-6 in CLL, several investigators54,55 have suggested that this molecule inhibits proliferation but prolongs survival (by suppressing apoptosis) of CLL cells. IL-10 in lymphoproliferative disorders Several other reports have demonstrated that serum IL-10 levels are elevated in patients with aggressive NHL26,32,35 and Hodgkin disease36 and are associated with a shorter failure-free survival and poor prognostic features. The source of IL-10, like that of IL-6, appears to be both the malignant cells as well as immunoregulatory cells in NHL.52 In our current study, we analyzed the serum levels of IL-10 in 159 CLL patients by using a methodology that detects both viral and human IL-10. We demonstrate that a serum level of IL-10 greater than 10 pg/mL is found in 34% of our patients. High serum IL-10 levels correlated with unfavorable phenotypic features of the disease such as advanced Rai stage, previous treatment, and elevated2-microglobulin and serum LDH. Serum IL-10 levels also
show significant correlation with the overall survival. The 3-year
survival for the group of patients with an elevated serum IL-10 was
45% (95% CI, 29%-61%), whereas the 3-year survival was 85% (95%
CI, 77%-93%) in patients with normal serum IL-10 levels
(P < .000001) (Figure 4).
The source of IL-10 in CLL appears to be polyclonal B cells rather than the leukemic cells.53 Study of the role of IL-10 in CLL has suggested that this molecule inhibits proliferation.56 In regard to survival, some investigators57 suggest that IL-10 prevents apoptotic death of CLL cells, whereas58 others suggest that it enhances it. Interestingly, we have noted that assays measuring both human and viral IL-10 yield significantly higher serum IL-10 levels in CLL patients than assays measuring only human IL-10. A similar phenomenon has been described in NHL.35 In that disease, levels of IL-10, as assessed by assays recognizing both human and viral forms, were found to be an independent prognostic factor in multivariate analysis; human IL-10 levels showed little to no correlation with prognosis.32-35 Because viral IL-10 is an EBV-derived molecule, we are currently investigating whether EBV is present and plays a role in CLL, as well as other lymphoid malignancies. Combined IL-6 and IL-10 When a combination of IL-6 and IL-10 levels was used, 3 different prognostic groups emerged: no elevation of these cytokines, elevation of one of them, or both, with a 3-year survival of 89%, 50%, and 27%, respectively (P < .00001) (Figure 5). The combination of these cytokines was also an independent prognostic variable in multivariate analysis that incorporated well-established factors such as Rai stage, prior treatment, age, and LDH. However, when2-microglobulin was added to the analysis, it emerged as
the most important prognostic factor, and IL-6/IL-10 were no longer selected. These results confirm a report by Keating et
al59 that showed that 2-microglobulin is a
potent prognostic factor for CLL. Similar results have been found in
other malignancies. 2-Microglobulin is an MHC I-type
molecule, and its levels may be regulated, at least in part, by
endogenous cytokines. 2-Microglobulin levels may,
therefore, reflect the convergence of several cytokines, as well as
other pathways.
Submitted January 13, 2000; accepted September 1, 2000.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Razelle Kurzrock, Department of Bioimmunotherapy, Box 302, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.
1. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990;8:253-278[Medline] [Order article via Infotrieve].
2.
Kishimoto T.
The biology of interleukin-6.
Blood.
1989;74:1-10 3. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621-636[Medline] [Order article via Infotrieve].
4.
Yee CY, Biondi A, Wang XH, et al.
A possible autocrine role for interleukin-6 in two lymphoma cell lines.
Blood.
1989;74:798-804 5. Chang H, Jamal N, Wang X-H, Minden MD, Messner HA. Constitutive production of the IL-5 and IL-6 by the lymphoma cell line OCI-Ly 17 derived from a patient with malignant lymphoma and hypereosinophilia. Leuk Lymphoma. 1992;8:97-107[Medline] [Order article via Infotrieve]. 6. Takeshita M, Sumiyoshi Y, Masuda Y, et al. Cytokine (Interleukin-1 alpha, Interleukin-1 beta, tumor necrosis factor alpha, and Interleukin-6)-possessing cells in lymph nodes of malignant lymphoma. Pathol Res Pract. 1993;189:18-25[Medline] [Order article via Infotrieve]. 7. Hsu S-M, Xie S-S, Waldron JA Jr. Functional heterogeneity and pathogenic significance of Interleukin-6 in B-cell lymphomas. Am J Pathol. 1992;141:915-923[Abstract]. 8. Freeman GJ, Freedman AS, Rabinowe SN, et al. Interleukin-6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989;83:1512-1518. 9. Muller H, Takeshita M, Krause J, Schuster K, Kikushi M, Stutle HJ. Immunohistochemical in situ demonstration of cytokines in Hodgkin's and non-Hodgkin's lymphoma. Verh Dtsch Ges Pathol. 1992;76:164-168[Medline] [Order article via Infotrieve].
10.
Pluda JM, Venzon DJ, Tosato G, et al.
Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe immunodeficiency virus infection receiving antiretroviral therapy.
J Clin Oncol.
1993;11:1099-1107
11.
Scala G, Quinto I, Ruocco MR, et al.
Expression of an exogenous interleukin-6 gene in human Epstein-Barr virus B cells confers growth advantage and tumorigenicity.
J Exp Med.
1990;172:61-68 12. Woodroofe C, Muller W, Ruther U. Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol. 1992;11:587-592[Medline] [Order article via Infotrieve]. 13. Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JLC. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest. 1993;91:2806-2814.
14.
Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R.
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.
J Clin Oncol.
1995;13:575-582
15.
Preti AH, Cabanillas F, Talpaz M, Tucker S, Seymour J, Kurzrock R.
Prognostic value of serum interleukin-6 in diffuse large cell lymphoma.
Ann Intern Med.
1997;127:186-194 16. Gause A, Scholz R, Klein S, et al. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease. Hematol Oncol. 1991;9:307-313[Medline] [Order article via Infotrieve].
17.
Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M.
Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Cancer Res.
1993;53:2118-2122 18. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease. Am J Med. 1997;102:21-28[Medline] [Order article via Infotrieve]. 19. Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma. 1998;30:563-571[Medline] [Order article via Infotrieve].
20.
Blay JY, Negrier S, Combaret V, et al.
Serum level of interleukin 6 as a prognosis factor in metastatic renal carcinoma.
Cancer Res.
1992;50:3317-3322 21. Twillie DA, Eisenberger MA, Carducce MA, Hseih W-S, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 1995;45:542-549[CrossRef][Medline] [Order article via Infotrieve]. 22. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164:1038-1043[Medline] [Order article via Infotrieve].
23.
Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H.
Inteleukin-6 is a prognostic factor in multiple myeloma.
Blood.
1991;77:2794-2795 24. Nachbaur DM, Herold M, Maneschg A, Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol. 1991;62:54-58[CrossRef][Medline] [Order article via Infotrieve].
25.
Fiorentino DF, Bond MW, Mosmann TR.
Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by the Th1 clones.
J Exp Med.
1989;170:2081-2095
26.
Benjamin D, Knobloch TJ, Dayton MA.
Human B-cell Interleukin-10: B-cell derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin 10.
Blood.
1992;80:1289-1298
27.
O'Garra A, Stapleton G, Dhar V, et al.
Production of cytokines by mouse B-cells: lymphomas and normal B-cells produce interleukin 10.
Int Immunol.
1990;2:821-832 28. O'Garra A, Chang R, Hastings R, Go N, Haughton G, Howard M. Lyl B (B-1) cells are the main source of B-cell derived IL-10. Eur J Immunol. 1992;22:711-717[Medline] [Order article via Infotrieve].
29.
Go NF, Castle BE, Barrett R, et al.
Interleukin-10 (IL-10), a new B-cell stimulatory factor: unresponsiveness of X-chromosome linked immunodeficiency B cells.
J Exp Med.
1990;172:1625-1631 30. Rousset F, Garcia E, Defrance T, et al. IL-10 is a potent growth factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992;898:1890-1893.
31.
Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick D.
Interleukin-10: a novel stimulator factor for mast cells and their progenitors.
J Exp Med.
1991;173:507-510
32.
Blay J-Y, Burdin N, Rousset F, et al.
Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor.
Blood.
1993;82:2169-2174 33. Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma. 1997;28:251-259.
34.
Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R.
Serum levels of interlukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis.
Blood.
1995;85:2516-2520
35.
Blay J-Y, Voorzanger N, Favrot M, Burdin N, Rousset F, Banchereau J.
Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with human immunodeficiency virus-related diffuse large-cell non-Hodgkin's lymphomas [letter].
Blood.
1995;86:4702-4707
36.
Sarris AH, Kliche K-O, Pethambaran P, et al.
Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.
Ann Oncol.
1999;10:433-440
37.
Cheson BD, Bennett JM, Grever M, et al.
National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
Blood.
1996;87:4990-4997 38. Gaines Das RE, Poole S. The international standard for interleukin-6: evaluation in an international collaborative study. J Immunol Methods. 1993;160:147-153[CrossRef][Medline] [Order article via Infotrieve].
39.
Reuben JM, Lee B-N, Johnson H, Fritsche H, Kantarjian HM, Talpaz M.
Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon- 40. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481[CrossRef]. 41. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames, IA: Iowa State University; 1980. 42. Altman DG. Practical Statistics for Medical Research. 1st ed. London: Chapman & Hall; 1991. 43. Stasi R, Conforti M, Del Poeta G, et al. Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas. Haematologica. 1992;77:18-21. 44. Yee C, Sutcliffe S, Messner HA, Minden MD. Interleukin-6 levels in the plasma of patients with lymphoma. Leuk Lymphoma. 1992;7:123-129[Medline] [Order article via Infotrieve]. 45. Stasi R, Stipa E, Masi M, et al. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myelogenous leukemia and non-Hodgkin's lymphoma. Thromb Haemost. 1993;70:568-572[Medline] [Order article via Infotrieve]. 46. Emilie D, Devergne O, Raphael M, Coumbaras CJ, Galanaud D. Production of interleukin-6 in high-grade B lymphomas. Curr Top Microbiol Immunol. 1992;182:349-355[Medline] [Order article via Infotrieve].
47.
Emilie D, Coumbaras J, Raphael M, et al.
Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblast in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients.
Blood.
1992;80:498-504 48. Ni K, O'Neill HC. Proliferation of the BCL1 B cell lymphoma induced by IL-4 and IL-5 is dependent on IL-6 and GM-CSF. Immunol Cell Biol. 1992;70:315-322.
49.
Shimizu S, Hirano T, Yoshioka R, et al.
Interleukin-6 (B-cell stimulatory factor-2)-dependent growth of a Lennert's lymphoma-derived T-cell line (KT-3).
Blood.
1988;72:1826-1828
50.
May LT, Helfgott DC, Sehgal PB.
Anti- 51. Dansky Ullmann C, Sclom J, Greiner JW. In vitro regulation of carcinoembryonic antigen (CEA) and class I HLA expression in human colon xenografts by interleukin-6 (IL-6) and the possible role of intrinsic interferon-induction [abstract 2710]. Proc Am Assoc Cancer Res. 1993;34:454.
52.
Voorzanger N, Touitou R, Barcia E, et al.
Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors.
Cancer Res.
1996;56:5499-5505 53. Lee BN, Estrov Z, Huh Y, et al. Peripheral blood normal polyclonal B cells from patients with B-CLL produce B-cell stimulatory cytokines [abstract 2758]. Proc Am Assoc Cancer Res. 1998;36.
54.
Aderka D, Maor Y, Novick D, et al.
Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta.
Blood.
1993;81:2076-2084 55. Reittie JE, Yong KL, Panayiotidis P, Hoffbrand AV. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukemia. Leuk Lymphoma. 1996;22:83-90[Medline] [Order article via Infotrieve]. 56. Tangye SG, Weston KM, Raison RL. Interleukin-10 inhibits the in vitro proliferation of human activated leukemic CD5+ B-cells. Leuk Lymphoma. 1998;31:121-130[Medline] [Order article via Infotrieve]. 57. Kitabayashi A, Kirokawa M, Miura AB. The role of interleukin-10 (IL-10) in chronic B-lymphocytic leukemia: IL-10 prevents leukemic cells from apoptotic cell death. Int J Hematol. 1995;62:99-106[CrossRef][Medline] [Order article via Infotrieve].
58.
Flckiger AC, Duran I, Banchereau J.
Interleukin-10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells.
J Exp Med.
1994;179:91-99
59.
Keating MJ, Lerner S, Kantarjian H, Freireich EJ, O'Brien S.
The serum
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. Gertner-Dardenne, C. Bonnafous, C. Bezombes, A.-H. Capietto, V. Scaglione, S. Ingoure, D. Cendron, E. Gross, J.-F. Lepage, A. Quillet-Mary, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies Blood, May 14, 2009; 113(20): 4875 - 4884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-E. Ariza, R. Glaser, P. T. P. Kaumaya, C. Jones, and M. V. Williams The EBV-Encoded dUTPase Activates NF-{kappa}B through the TLR2 and MyD88-Dependent Signaling Pathway J. Immunol., January 15, 2009; 182(2): 851 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Greiner, L. Bullinger, B.-a. Guinn, H. Dohner, and M. Schmitt Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells Clin. Cancer Res., November 15, 2008; 14(22): 7161 - 7166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Fanourgiakis, E Mylona, I I Androulakis, C Eftychiou, E Vryonis, A Georgala, A Skoutelis, and M Aoun Non-Hodgkin's lymphoma and tuberculosis coexistence in the same organs: a report of two cases Postgrad. Med. J., May 1, 2008; 84(991): 276 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Sellick, R. Wade, S. Richards, D. G. Oscier, D. Catovsky, and R. S. Houlston Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis Blood, February 1, 2008; 111(3): 1625 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Kater, M. H. J. van Oers, and T. J. Kipps Cellular immune therapy for chronic lymphocytic leukemia Blood, October 15, 2007; 110(8): 2811 - 2818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gary-Gouy, A. Sainz-Perez, J.-B. Marteau, A. Marfaing-Koka, J. Delic, H. Merle-Beral, P. Galanaud, and A. Dalloul Natural Phosphorylation of CD5 in Chronic Lymphocytic Leukemia B Cells and Analysis of CD5-Regulated Genes in a B Cell Line Suggest a Role for CD5 in Malignant Phenotype J. Immunol., October 1, 2007; 179(7): 4335 - 4344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Benoliel, J. Epstein, E. Eliav, R. Jurevic, and S. Elad Orofacial Pain in Cancer: Part I--Mechanisms Journal of Dental Research, June 1, 2007; 86(6): 491 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. McWhirter, A. Kretz-Rommel, A. Saven, T. Maruyama, K. N. Potter, C. I. Mockridge, E. P. Ravey, F. Qin, and K. S. Bowdish Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation PNAS, January 24, 2006; 103(4): 1041 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wu, R. Gessner, T. Taube, A. von Stackelberg, G. Henze, and K. Seeger Expression of Interleukin-10 Splicing Variants Is a Positive Prognostic Feature in Relapsed Childhood Acute Lymphoblastic Leukemia J. Clin. Oncol., May 1, 2005; 23(13): 3038 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Gricks, D. Zahrieh, A. J. Zauls, G. Gorgun, D. Drandi, K. Mauerer, D. Neuberg, and J. G. Gribben Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells Blood, December 15, 2004; 104(13): 4002 - 4009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lech-Maranda, L. Baseggio, J. Bienvenu, C. Charlot, F. Berger, D. Rigal, K. Warzocha, B. Coiffier, and G. Salles Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma Blood, May 1, 2004; 103(9): 3529 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Shanafelt and T. G. Call Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia Mayo Clin. Proc., March 1, 2004; 79(3): 388 - 398. [Abstract] [PDF]
|
|
|
|
|
|
T. D. Shanafelt, S. M. Geyer, and N. E. Kay Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL Blood, February 15, 2004; 103(4): 1202 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Trikha, R. Corringham, B. Klein, and J.-F. Rossi Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence Clin. Cancer Res., October 15, 2003; 9(13): 4653 - 4665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Orsini, A. Guarini, S. Chiaretti, F. R. Mauro, and R. Foa The Circulating Dendritic Cell Compartment in Patients with Chronic Lymphocytic Leukemia Is Severely Defective and Unable to Stimulate an Effective T-Cell Response Cancer Res., August 1, 2003; 63(15): 4497 - 4506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Asadullah, W. Sterry, and H. D. Volk Interleukin-10 Therapy--Review of a New Approach Pharmacol. Rev., June 1, 2003; 55(2): 241 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Helman Jr, J. C. Byrd, N. C. Ales, and A. F. Shorr Fludarabine-Related Pulmonary Toxicity* : A Distinct Clinical Entity in Chronic Lymphoproliferative Syndromes Chest, September 1, 2002; 122(3): 785 - 790. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
70°C) were obtained at diagnosis or
relapse. All patients were off treatment for at least 3 months. The
samples were derived from all consenting patients meeting the criteria
for analysis who were seen in a 1.5-year time period. All histological
material was reviewed at M. D. Anderson Cancer Center. The
patients were followed every 3 to 6 months while off treatment and more
often as necessary while on any treatment. Initial evaluation included
a medical interview; complete physical examination; complete blood and
platelet counts; serum chemistry; 
at a
concentration of these cytokines of 800 to 1000 ng/mL. The percentage
of cross-reactivity is estimated at 
0.005% in each case. The
recovery of IL-10 added to normal serum averages 93%. The intra-assay
coefficient of variation is 2.6% to 5.3% at 60.2 to 498.9 pg/mL, and
the interassay coefficient of variation is 2.8% to 6.1% at 61.8 to
499.9 pg/mL.
